Clinical Trials

Study Title:
The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer) CompassHER2 Residual Disease (RD), a Double-Blinded, Phase III Randomized Trial of T-DM1 Compared With T-DM1 and Tucatinib

For more information about the trial above please contact the study team:

Principal Investigator, Frank Brescia, at bresciaf@musc.edu.

Study Coordinator, Alexandria Green, at greealex@musc.edu.

Trial opened at the following institutions: Beaufort Memorial Hospital, Medical University of South Carolina, Tidelands Health